AGIC Capital Acquires a Majority Stake in Grafotronic
19.5.2022 12:23:00 EEST | Business Wire | Press release
AGIC Capital, the European-Asian private equity fund focused on investments in high quality industrial and medical companies today announced the acquisition of a majority stake in Grafotronic AB and its subsidiaries (“Grafotronic”), a leading manufacturer of roll-to-roll automated manufacturing solutions, from its current shareholders, for an undisclosed amount.
Established in 2004, Grafotronic develops highly distinctive modular solutions for the digital label finishing and EV battery markets. It has achieved substantial growth over the last five years since focusing on the digital finishing segment, and is building its position into manufacturing technologies for a range of products in the EV battery market in partnerships with major players in the field.
AGIC was attracted to Grafotronic’s positioning in resilient and high-growth markets, modular product concept, strong innovation capabilities including automation and product / services connectivity, asset-light business model, dedicated and dynamic management team and attractive financial profile. Partnering with the management team, AGIC will support Grafotronic’s continued international growth both in the digital finishing and EV battery segments, in the existing core European markets, US and Asia.
Håkan Sundqvist, Founder of Grafotronic, said: “This is an important step in achieving our dreams, fulfilling our aspirations as a company, and a sound business decision to secure a sustainable future. With the backing of AGIC, we can accelerate on realizing future growth potential, provide our customers with even more innovative solutions and at the same time significantly increase our production and R&D capacity. With AGIC, we can achieve our maximum development potential worldwide.”
Ben Mitchell, AGIC’s Director & Head of UK, said: “We are delighted to have made the investment into Grafotronic and to be backing the management team to deliver the next phase of growth. The acquisition of Grafotronic exemplifies AGIC’s investment strategy, to partner with the management teams of outstanding European SMEs which have significant growth potential and to provide proactive, hands-on support to realise that potential.”
About AGIC Capital
Founded in 2015, AGIC is a European-Asian fund focused on investments in advanced industrial and healthcare technology companies and has more than US$ 2.2 billion of assets under management. It targets buyout and growth- stage investment in small- and medium-sized companies and employs customized, hands-on approaches to guiding and supporting portfolio companies in developing and executing market penetration plans. AGIC has offices in Munich, London, Hong Kong, Shanghai and Beijing. For more information, please go to www.agic-group.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005895/en/
Contact information
AGIC Capital
Ben Mitchell
Email: ben.mitchell@agic-group.com
T: +44 20 3926 5513
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom